07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

Alpine Biosciences, Oncothyreon deal

Oncothyreon acquired drug delivery company Alpine for 9.2 million Oncothyreon shares, or about $27.1 million based on Oncothyreon's close of $2.93 on Aug. 8, before the deal was announced. Alpine is developing protocells, a nanoparticle...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Financial News

Alpine BioVentures financial update

Mitchell Gold, former president and CEO of immunotherapy cancer company Dendreon Corp. (NASDAQ:DNDN, Seattle, Wash.), and biotech analyst David Miller launched biotech hedge fund Alpine BioVentures. Miller said Alpine will start as a "modestly...
07:00 , Sep 9, 2013 |  BioCentury  |  Finance

Banker tracks

Banker tracks Matthew McAskin joined Evercore Partnersas a senior managing director in the firm's healthcare investment banking group. McAskin was a managing director and co-head of healthcare services investment banking at Goldman Sachs. Buyside tracks Carl Harald Janson...
00:39 , Sep 4, 2013 |  BC Extra  |  Financial News

Former Dendreon head, analyst launch biotech hedge fund

Mitchell Gold, former president and CEO of immunotherapy cancer company Dendreon Corp. (NASDAQ:DNDN), and biotech analyst David Miller launched biotech hedge fund Alpine BioVentures. Miller said Alpine will start as a "modestly sized fund" in...